the dose-related tolerance and histopathologic effects of intranasal recombinant interferon alpha-2a ( rifn-alpha 2a ) were determined in a blind study in which healthy subjects were randomized to receive sprays of interferon ( ifn ) ( 3 or 6 mu/day ) or placebo for 28 days .
C0021734
recombinant
C0021747
interferon